The White House on Friday said Novo Nordisk’s weight-loss drugs Wegovy and Ozempic were among the 15 medications picked for a ...

The Centers for Medicare and Medicaid Services (CMS) on Friday announced 15 additional Medicare Part D drugs selected for the ...

Mounjaro, like other GLP-1 drugs, carries potential side effects, including nausea, vomiting, dehydration, and hypoglycaemia ...

Tripling the dosage of the Wegovy weight-loss drug leads to more weight loss, Novo Nordisk said Friday.

The late-stage trial of semaglutide, which it markets as Wegovy to treat obesity, showed that those who took a dose of 7.2 milligrams lost an average of 20.7% of their weight over 72 weeks. A third of ...

Federal officials are targeting the blockbuster drugs as part of their ongoing initiative to lower drug costs.

When applying the treatment policy estimand 2, people treated with semaglutide 7.2 mg achieved a superior weight loss of 18.7% compared to a reduction of 15.6% with semaglutide 2.4 mg and 3.9% with ...

Novo Nordisk (NVO) stock slipped after ate-stage trial data for a higher-dose version of its popular obesity therapy, ...

Eli Lilly (NYSE: LLY) began a roll in late 2020 that lasted almost four years. During that time, it became the world's ...

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...

The CEO of obesity drugmaker Novo Nordisk and heads of other Danish companies met on Thursday with Denmark's Prime Minister Mette Frederiksen to discuss preparations for a ...